Parecoxib is a water-soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx). As it is injectable, it can be used perioperatively when patients are unable to take oral medications. It is approved through much of Europe for short term perioperative pain control much in the same way ketorolac (Toradol) is used in the United States. A letter of non-approval for parecoxib was issued by the FDA in 2005.
Used for short term perioperative pain control.
Department of Anesthesiology,,The first affiliated hospital of Sun Yat-Sen university, Guangzhou, Guangdong, China
Baerum Hospital, Rud, Norway
Department of Anesthesiology, Faculty of Medicine, Maung, Chiang Mai, Thailand
Department of Anesthesiology, Faculty of Medicine, Chiang Mai University, Maung, Chiang Mai, Thailand
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Ullevaal University Hospital, Oslo, Norway
Pfizer Investigational Site, Oxford, United Kingdom
Pfizer Investigational Site, Lima, Peru
Royal Melbourne Hospital, Melbourne, Victoria, Australia
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.